Skip to Content

Pravastatin Pregnancy and Breastfeeding Warnings

Pravastatin is also known as: Pravachol

Pravastatin Pregnancy Warnings

Pravastatin has been assigned to pregnancy category X by the FDA. Animal studies using pravastatin failed to reveal evidence of teratogenicity, however, studies with other HMG-CoA reductase inhibitors revealed an increased incidence of skeletal malformations. HMG-CoA reductase inhibitors are known to inhibit biosynthetic processes necessary for fetal development. There are no controlled data in human pregnancy. Pravastatin use is considered contraindicated during pregnancy.

Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they are contraindicated during pregnancy and in nursing mothers.

See references

Pravastatin Breastfeeding Warnings

Small quantities of pravastatin are excreted into human milk. The manufacturer considers pravastatin to be contraindicated during lactation.

The excretion of pravastatin into breast milk was evaluated in 11 women following oral administration of 20 mg of pravastatin orally twice a day for a total of five doses. The maximum concentrations of pravastatin and its major metabolite in milk following the last dose averaged 3.9 ng/mL and 2.1 ng/mL, respectively.

See references

References for pregnancy information

  1. "Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb, Princeton, NJ.

References for breastfeeding information

  1. Pan HY "Clinical pharmacology of pravastatin, a selective inhibitor of HMG- CoA reductase." Eur J Clin Pharmacol 40 (1991): s15-8
  2. "Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb, Princeton, NJ.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.